Search

Displaying results 1101 - 1110 of 7536 in total
  1. Drug

    Metreleptin

    go.drugbank.com/drugs/DB09046
    ApprovedInvestigational

    [L41315] Metreleptin was approved by Health Canada in January 2024 for the same patient population, in addition to patients with partial lipodystrophy.[L49901] … [L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized

    Synonyms: N-Methionylleptin
  2. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.

  3. Drug

    CX-052075

    go.drugbank.com/drugs/DB31655
    Approved

    [L53408,L53423] The original approval was formulated with the JN.1 strain ([mRNA-1283]), but was ultimately updated to the sublineage LP.8.1.[L54586] … [L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna.

  4. Drug

    Ibalizumab

    go.drugbank.com/drugs/DB12698
    ApprovedInvestigational

    In October 2022, the FDA approved the administration of Trogarzo (ibalizumab-uiyk) by intravenous push, allowing for a faster drug administration.[L43443,L43448] … It has been developed by Taimed biologics and Theratechnologies [L1558, L1554]. This drug was approved in March 2018 for the management of treatment-resistant HIV [L1554].

  5. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    [L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … important for the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key resistance mechanism to

    Mixtures: Avmapki Fakzynja Co-packSynonyms: N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide
  6. Drug

    Thrombin

    go.drugbank.com/drugs/DB11300
    ApprovedInvestigational

    Medical thrombin is a protein substance produced through a conversion reaction in which prothrombin of bovine origin is activated by tissue thromboplastin in the presence of calcium chloride. … Thrombin requires no intermediate physiological agent for its action. It clots the fibrinogen of the blood directly.

  7. Drug

    Betamethasone

    go.drugbank.com/drugs/DB00443
    ApprovedInvestigationalVet approved

    [A192444] It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders.

    Mixtures: Throwers Pbc No. 1, TUDERM-N
  8. Drug

    Mupirocin

    go.drugbank.com/drugs/DB00410
    ApprovedInvestigationalVet approved

    _ and traumatic skin lesions due to secondary skin infections caused by _S. aureus_ and _S. pyogenes_. … [L10580] It is available in topical formulations only due to extensive systemic metabolism[A178531] and is used in the treatment of impetigo caused by _Staphylococcus aureus_ and _Streptococcus pyogenes

  9. Drug

    Cephaloglycin

    go.drugbank.com/drugs/DB00689
    Approved

    A cephalorsporin antibiotic that is no longer commonly used.

  10. Drug

    Pexidartinib

    go.drugbank.com/drugs/DB12978
    ApprovedInvestigational

    Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor … [L7895] Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors.